Posted by Michael Wonder on 05 Sep 2023
Abliva’s lead candidate KL1333 receives FDA fast track designation
4 September 2023 - Abliva today announced that the company’s lead candidate KL1333 has received fast track designation from the US FDA, facilitating its clinical development and path forward to market.
Abliva’s lead drug candidate KL1333 is currently being evaluated in the FALCON study, a global, potentially registrational, Phase 2 study in mitochondrial disease patients.
